← GLP-1

What podcasts say about GLP-1

Every statement, with the speaker, the exact quote and the moment it was said.

What experts have said about GLP-1

25 statements · 15 positive · 9 negative · 1 mixed

  1. Direct-to-consumer GLP-1 access can lower prices while increasing drugmaker revenue

    “Prices go from $1,300 to $149. and the people making the drugs are making more money.”

    Listen at 8:30

    Open the episode · Zach Reitano - Building Ro and Why Healthcare Should Be 50% of GDP - [Invest Like the Best, EP.500]
  2. GLP-1 inventors should capture more margin than access providers

    “the inventors of GLP-1s should grab more margin than the people who scale access to debt.”

    Listen at 14:58

    Open the episode · Zach Reitano - Building Ro and Why Healthcare Should Be 50% of GDP - [Invest Like the Best, EP.500]
  3. Travis HoiumNegativeNov 6, 2026· Chit Chat Stocks

    GLP-1 prices fell approximately 90% after Hims & Hers began compounding products.

    “Since that, since hims and hers started compounding, the price of GLP ones is down around 90%.”

    Listen at 38:37

    Open the episode · The AI Market Crash Is Here; Reddit, Axon, And Uber Earnings; Asymmetric Stocks With Travis Hoium
  4. Jan Van EckNegativeNov 5, 2026· The Pomp Podcast

    New technologies such as GLP-1 drugs will prevent major healthcare-cost declines.

    “i can't see healthcare costs coming down so much because there will be new technologies like glp ones that people want to spend money on”

    Listen at 18:09

    Open the episode · Bitcoin Is the Hedge Against a U.S. Default Nobody Sees Coming | Jan Van Eck
  5. Daniel Müller is increasingly uncertain about GLP-1 drugs’ business impact.

    “the more I learn about them, the more uncertain I am.”

    Listen at 49:34

    Open the episode · TIP858: McDonald's ($MCD): Generational Compounder in Historical Drawdown w/ Daniel Mahncke & Shawn O'Malley
  6. GLP-1 drugs pose a growing global challenge to McDonald’s.

    “this gives a whole lot more reason to believe that this is a challenge that's not going to fade away for McDonald's and will only continue to grow globally”

    Listen at 58:37

    Open the episode · TIP858: McDonald's ($MCD): Generational Compounder in Historical Drawdown w/ Daniel Mahncke & Shawn O'Malley
  7. GLP-1 drugs may be McDonald’s most powerful threat in decades.

    “that's probably the most powerful threat that we have had McDonald's seeing in probably decades, if not ever.”

    Listen at 59:12

    Open the episode · TIP858: McDonald's ($MCD): Generational Compounder in Historical Drawdown w/ Daniel Mahncke & Shawn O'Malley
  8. People taking GLP-1 drugs typically lose approximately equal amounts of fat and muscle.

    “typically speaking, about 50% of the weight that someone loses is fat and 50% muscle.”

    Listen at 33:07

    Open the episode · WHOOP CEO, Will Ahmed: 50B Hours of Health Data, a 4 Million Member Data Moat, & the FDA Fight
  9. Craig Fuller reports losing 50 pounds while taking a GLP-1 medication.

    “I've lost 50 pounds”

    Listen at 10:55

    Open the episode · "No Signs Of The A.I. Party Slowing Down" | Craig Fuller
  10. Richard MottNegativeOct 24, 2026· Odd Lots

    GLP-1 medications are likely affecting fine-dining consumption patterns.

    “I'm sure it is affecting”

    Listen at 42:13

    Open the episode · How a Chicago Restaurant Has Stayed Open For Nearly Three Decades
  11. Scott KanoskiPositiveOct 12, 2026· Huberman Lab

    Peripheral and central GLP-1 independently suppress hunger.

    “The peripheral GLP-1 and the central GLP-1 have very similar effects. So they're involved in hunger suppression, but they seem to be operating independently.”

    Listen at 4:05

    Open the episode · How Food Choices Shape Memory, Cognition & Cravings | Dr. Scott Kanoski
  12. Scott KanoskiPositiveOct 12, 2026· Huberman Lab

    Peripheral and central GLP-1 both suppress appetite

    “But they do both have appetite suppressing effects.”

    Listen at 4:21

    Open the episode · How Food Choices Shape Memory, Cognition & Cravings | Dr. Scott Kanoski
  13. Scott KanoskiPositiveOct 12, 2026· Huberman Lab

    GLP-1 regulates blood glucose and stimulates insulin secretion during hyperglycemia.

    “they're helping to regulate blood glucose levels, to stimulate insulin secretion when there's high levels of glucose present in the blood.”

    Listen at 4:28

    Open the episode · How Food Choices Shape Memory, Cognition & Cravings | Dr. Scott Kanoski
  14. Scott KanoskiPositiveOct 12, 2026· Huberman Lab

    GLP-1 promotes satiation largely through vagal paracrine signaling.

    “GLP-1 is a big player in that process. Not exclusively through the vagus nerve, but probably largely through the vagus nerve, through this paracrine mode of action.”

    Listen at 15:24

    Open the episode · How Food Choices Shape Memory, Cognition & Cravings | Dr. Scott Kanoski
  15. Chloe MelleyNegativeSep 11, 2026· Stock Movers

    Generic competition will emerge for GLP-1s in some markets

    “generic competition is going to start coming quite soon”

    Listen at 1:05

    Open the episode · Novo Nordisk Drops, Puma Down, Trainline Rises
  16. Emily CohnPositiveSep 10, 2026· Bloomberg Intelligence

    Cheaper GLP-1 generics could become a major tailwind for retailers.

    “as the competition heats up as when generics eventually hit the market they're already hitting the market in countries like brazil this is going to be a huge potential tailwind for the retailers”

    Listen at 5:24

    Open the episode · Macy’s Falls on Guidance Despite Sales Beat, Better Outlook
  17. Emily CohnPositiveSep 10, 2026· Bloomberg Intelligence

    Cheaper and generic GLP-1 drugs could strongly benefit retailers.

    “this is going to be a huge potential tailwind for the retailers”

    Listen at 5:30

    Open the episode · Macy’s Falls on Guidance Despite Sales Beat, Better Outlook
  18. Jim CramerPositiveSep 8, 2026· Mad Money w/ Jim Cramer

    GLP-1 drugs will be effective for COPD.

    “I do think GOP-1 is going to be really good on COPD.”

    Listen at 39:19

    Open the episode · 'Mad Money w/ Jim Cramer 9/8/26
  19. GLP-1 medicines will continue expanding strongly

    “the GLP ones, they're clearly just going to continue to power on”

    Listen at 39:41

    Open the episode · Knowing when to sell: How growth investor Michael Frazis manages risk
  20. GLP-1 product penetration increased significantly over the past year

    “Penetration for GLP One products have been increasing significantly, I would say, in the past year”

    Listen at 30:24

    Open the episode · Meta Says It Will Pay Up to $18 Billion Over Social Media Claims
  21. GLP-1 adoption has created headwinds for food companies

    “definitely they have been some headwinds”

    Listen at 30:56

    Open the episode · Meta Says It Will Pay Up to $18 Billion Over Social Media Claims
  22. Obesity rates are falling slightly, partly because of GLP-1 drugs.

    “We're seeing obesity rates falling, although only slightly because of GLP-1s.”

    Listen at 54:06

    Open the episode · David Wallace-Wells:  The Politics of AI Are Shifting in Real Time
  23. Abud BakriPositiveJun 1, 2026· Huberman Lab

    GLP-1 peptides have stronger clinical effects than obscure peptides lacking clear targets.

    “the GLP1s, which have a very strong clinical effect compared to these obscure peptides like BBC157, TB500, TB4, that don't have a clear target.”

    Listen at 4:46

    Open the episode · Peptides: The Science, Uses & Safety | Dr. Abud Bakri
  24. Waters supplies separation columns used in quality control by major GLP-1 manufacturers.

    “For both of the large GLP-1 manufacturers, our columns are used in quality control.”

    Listen at 29:59

    Open the episode · Mad Money w/ Jim Cramer 5/5/26
  25. Jim CramerNegativeOct 6, 2025· Mad Money w/ Jim Cramer

    GLP-1 drugs from Eli Lilly and Novo Nordisk have severely harmed sleep-apnea investments.

    “anything related to sleep apnea has been eviscerated by the rise of the GOP-1 weight loss drugs from Eli Lilly and Novo Nordics.”

    Listen at 28:53

    Open the episode · Mad Money w/ Jim Cramer 10/6/25

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.